Table 3.
Mean and standard deviation of MG-ADL and QMG scores at the beginning and at the end of each cycle of therapy with Efgartigimod.
| MG-ADL assessment in all patients | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1° Cycle | 2° Cycle | 3° Cycle | p value* | ||||||||
| MG-ADL | T0 | T3 | T0 | T3 | T0 | T3 | 1° Cycle | 2° Cycle | 3° Cycle | 1°-2° Cycle | 1°-3° Cycle |
| mean | 7.5 | 4.0 | 5.8 | 3.1 | 7.7 | 4.0 | 0.007 | 0.010 | 0.0009 | 0.0003 | 0.016 |
| SD | 2.6 | 2.7 | 4.1 | 1.5 | 3.4 | 2.8 | |||||
| QMG assessment in all patients | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1° cycle | 2° cycle | 3° cycle | p value* | ||||||||
| QMG | T0 | T3 | T0 | T3 | T0 | T3 | 1° Cycle | 2° Cycle | 3° Cycle | 1°-2° Cycle | 1°-3° Cycle |
| mean | 12.8 | 9.2 | 12.2 | 9.3 | 13.0 | 10.1 | 0.010 | 0.035 | 0.004 | 0.007 | 0.043 |
| SD | 4.1 | 4.7 | 6.8 | 4.3 | 4.4 | 4.8 | |||||
* Repeated measures ANOVA with Post Hoc analysis using Bonferroni method.